@article{10.37349/ei.2022.00066,
abstract = {Human γδ T cells are unconventional lymphocytes that function in innate and adaptive immune responses and immunosurveillance. These cells show potent cytotoxicity against tumor cells in a major histocompatibility complex unrestricted manner and have recently gained considerable attention as a sparkling star for clinical immunotherapy. Clinical immunotherapy trials with activated γδ T cells are tolerated well. However, clinical benefits are still unsatisfactory. Therefore, anti-tumor effects need to further increase the cytotoxicity of γδ T cells via several mechanisms, including the novel nitrogen-containing bisphosphonate products, adjuvant use with a bispecific antibody and chimeric antigen receptor, co-immunotherapy with γδ T cells plus immune checkpoint inhibitors, and adoptive immunotherapy with Vδ1 T cells and T cells engineered to express a defined γδ T cell receptor. Here, this article describes the crucial role of γδ T cells in anti-tumor immunity, concludes transduction strategies and summarizes the different development of novel approaches for clinical applications and cancer immunotherapy, which may be effective in overcoming current therapeutic limitations.},
author = {Zheng, Jiamian and Jiang, Xuan and Zhao, Haotian and Wang, Wandi and Wu, Xiuli and Jin, Zhenyi},
doi = {10.37349/ei.2022.00066},
journal = {Exploration of Immunology},
pages = {540--557},
title = {{γδ T cells: a sparkling star for clinical immunotherapy}},
url = {https://www.explorationpub.com/Journals/ei/Article/100366},
volume = {2},
year = {2022},
number = {4}
}